Senti Biosciences Holdings, Inc. [SNTI] - Senti Biosciences / Celadon Partners SPV 35 merger
Senti Biosciences Holdings, Inc. has entered into a definitive merger agreement with Celadon Partners SPV 35 Limited, where Senti Merger Sub, Inc. will merge with Senti Holdings, Inc., with the transaction aimed at advancing gene therapy developments for Rett syndrome and TIL therapies.
Why this matters
Senti Biosciences Holdings, Inc., a company focused on developing synthetic biology solutions, particularly in gene and cell therapy, has entered into a definitive merger agreement with Celadon Partners SPV 35 Limited. This strategic move involves Senti Merger Sub, Inc. merging with Senti Holdings, Inc., with the aim of advancing gene therapy developments for Rett syndrome and tumor-infiltrating lymphocyte (TIL) therapies. Following the merger, Senti plans to leverage its expertise in gene circuits and artificial intelligence to enhance its therapeutic offerings, focusing initially on its proprietary Regulator Dial platform. The merger agreement includes a requirement for additional funding through the purchase of Senior Secured Convertible Notes, with a specified amount of $6 million, minus proceeds from existing stock sales, to support these strategic initiatives.